Adaptimmune Therapeutics's total assets for Q2 2025 were $130.63M, a decrease of -17.36% from the previous quarter. ADAP total liabilities were $201.59M for the fiscal quarter, a 3.12% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.